No Data
No Data
Casella Waste Systems, SES AI And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Ladenburg Thalmann Maintains Buy on Corvus Pharma, Raises Price Target to $21
Corvus Pharma Analyst Ratings
Ladenburg Thalmann Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $21
Ladenburg Thalmann analyst Aydin Huseynov maintains $Corvus Pharmaceuticals(CRVS.US)$ with a buy rating, and adjusts the target price from $12 to $21.According to TipRanks data, the analyst has a
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
Corvus Spikes as Late-stage Trial for Lead Asset Announced